AstraZeneca Plc and Bristol-Myers Squibb Co. have received for their diabetes-2-Medium "Onglyza" marketing approval from the European Commission. "The decision marks the European Commission an important milestone in the cooperation of both companies," said Bristol-Europe president Beatrice Cazala on Monday. The Diabetes 2 funding is the first jointly-developed drug that is marketed by both companies in Europe to market. In Europe suffer according to the company about 53 million people with diabetes. The U.S. Food and Drug Administration had already given its approval for Onglyza in July.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment